he US Drug Administration (FDA) has approved a treatment to prevent migraine, which should be available within a week in the United States, announced Thursday the Swiss pharmaceutical companies Novartis and Amgen American.
This treatment, called Aimovig, was designed to be administered by the patients themselves, once a month using an injection pen similar to insulin pens.
This is an “innovative approach” and “the first and only FDA-approved treatment specifically developed to prevent migraine headaches by blocking the calcitonin gene-related peptide receptor (CGRP-R),” said Novartis and Amgen in a statement.
“Aimovig is the first treatment of its kind to target this receptor and has shown strong efficacy against migraines,” said Novartis CEO Paul Hudson, quoted in the text.
In the United States, Aimovig will cost $ 575 for a monthly injection of 70 or 140 mg, or $ 6900 a year, according to the statement.
Novartis said it expects approval of treatment in the European Union in the coming months.